/ACHL

ACHL Stock - Achilles Therapeutics plc

Q: What is the analyst price target for ACHL?

Analyst price target information is not currently available for ACHL.

Q: What is ACHL's market cap?

Market capitalization information is not currently available for ACHL.

Healthcare|Biotechnology|NASDAQ

$1.48+0.68%

+$0.01 (+0.68%) • Mar 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+35.1%upside

Target: $2.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ACHL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.25

52W High$1.51

52W Low$0.63

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-4,731,267	$-3,687,722	$-3,287,608	$-778,005	$-303,250
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-75,255,000	$-78,383,000	$-64,195,000	$-33,727,000	$-13,775,000
Net Income	$-69,665,000	$-71,176,000	$-61,099,000	$-33,199,000	$-13,990,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.74	$-1.82	$-2.13	$-0.82	$-20.50

Company Overview

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish1 Neutral/Bearish

Price Targets

Average Target

↑ 35.1% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
April 5th 2024	Piper Sandler	Downgrade	Neutral	$2← $8

Earnings History & Surprises

ACHL

Beat Rate

31%

Last 16 quarters

Avg Surprise

-24.7%

EPS vs Estimate

Beats / Misses

5/9

2 met exactly

Latest EPS

$-0.46

Q2 2025

EPS Surprise History

Q2 23

-7.3%

$-0.44vs$-0.41

Q3 23

-5.0%

$-0.42vs$-0.40

Q4 23

-10.5%

$-0.42vs$-0.38

Q1 24

-228.6%

$-0.46vs$-0.14

Q2 24

0.0%

$-0.46vs$-0.46

Q3 24

0.0%

$-0.41vs$-0.41

Q4 24

-17.1%

$-0.48vs$-0.41

Q2 25

-27.8%

$-0.46vs$-0.36

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 12, 2025	—	—	—	—
Q3 2025	Aug 12, 2025	—	—	—	—
Q2 2025	May 6, 2025	—	—	—	—
Q2 2025	Apr 3, 2025	$-0.36	$-0.46	-27.8%	✗ MISS
Q4 2024	Nov 14, 2024	$-0.41	$-0.48	-17.1%	✗ MISS
Q3 2024	Aug 14, 2024	$-0.41	$-0.41	0.0%	= MET
Q2 2024	Apr 4, 2024	$-0.46	$-0.46	0.0%	= MET
Q1 2024	Mar 26, 2024	$-0.14	$-0.46	-228.6%	✗ MISS
Q4 2023	Nov 13, 2023	$-0.38	$-0.42	-10.5%	✗ MISS
Q3 2023	Aug 4, 2023	$-0.40	$-0.42	-5.0%	✗ MISS
Q2 2023	May 10, 2023	$-0.41	$-0.44	-7.3%	✗ MISS
Q1 2023	Mar 7, 2023	$-0.42	$-0.61	-45.2%	✗ MISS
Q4 2022	Nov 8, 2022	$-0.55	$-0.32	+41.8%	✓ BEAT
Q3 2022	Aug 9, 2022	$-0.57	$-0.44	+22.8%	✓ BEAT
Q2 2022	May 10, 2022	$-0.51	$-0.45	+11.8%	✓ BEAT
Q1 2022	Mar 1, 2022	$-0.41	$-0.45	-9.8%	✗ MISS
Q4 2021	Nov 9, 2021	$-0.48	$-0.34	+29.2%	✓ BEAT
Q3 2021	Aug 10, 2021	$-0.49	$-0.45	+8.2%	✓ BEAT
Q2 2021	May 11, 2021	$-3.25	$-8.38	-157.8%	✗ MISS
Q1 2021	Mar 1, 2021	—	$-5.00	—	—

Frequently Asked Questions about ACHL

What is ACHL's current stock price?

Achilles Therapeutics plc (ACHL) is currently trading at $1.48 per share. The stock has moved +0.68% today.

What is the analyst price target for ACHL?

The average analyst price target for ACHL is $2.00, based on 1 analyst.

What sector is Achilles Therapeutics plc in?

Achilles Therapeutics plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ACHL's market cap?

Achilles Therapeutics plc has a market capitalization of $0.06 billion, making it a small-cap company.

Does ACHL pay dividends?

No, Achilles Therapeutics plc does not currently pay a dividend to shareholders.